CEFTOLOZANE PHARMACEUTICAL COMPOSITIONS
Pharmaceutical compositions can include an amount of sodium chloride effective to stabilize ceftolozane in an antibiotic formulation.
1 . A pharmaceutical composition comprising 125 mg to 500 mg sodium chloride per 1,000 mg of ceftolozane active, wherein the decrease in ceftolozane total purity is not greater than about 4% after storing the pharmaceutical composition for seven days in a sealed container at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.
2 . The pharmaceutical composition of claim 1 , further comprising L-arginine.
3 . The pharmaceutical composition of claim 1 , further comprising citric acid.
4 . The pharmaceutical composition of claim 2 , further comprising citric acid.
5 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for parenteral administration.
6 . The pharmaceutical composition of claim 5 , wherein the composition is a unit dosage form in a vial comprising 125 mg to 500 mg sodium chloride, 1,000 mg of ceftolozane in the form of ceftolozane sulfate, L-arginine and citric acid.
7 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is lyophilized.
8 . The pharmaceutical composition of claim 1 , wherein the ceftolozane is ceftolozane sulfate.
9 . A pharmaceutical composition comprising 125 mg to 500 mg sodium chloride per 1,000 mg of ceftolozane active, wherein the increase in the amount of the impurity represented by Peak 1 is not greater than about 2% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C., where Peak 1 has a retention time relative to ceftolozane of about 0.1.
10 . The pharmaceutical composition of claim 9 , further comprising L-arginine.
11 . The pharmaceutical composition of claim 9 , further comprising citric acid.
12 . The pharmaceutical composition of claim 10 , further comprising citric acid.
13 . The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is formulated for parenteral administration.
14 . The pharmaceutical composition of claim 13 , wherein the composition is a unit dosage form comprising 125 mg to 500 mg sodium chloride, 1,000 mg of ceftolozane in the form of ceftolozane sulfate, L-arginine and citric acid.
15 . The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is lyophilized.
16 . The pharmaceutical composition of claim 9 , wherein the ceftolozane is ceftolozane sulfate.
17 . A unit dosage form injectable pharmaceutical composition comprising 125 mg to 500 mg sodium chloride and 1,000 mg of ceftolozane active present as a composition of formula (I)
18 . A solid pharmaceutical composition comprising 125 mg to 500 mg sodium chloride per 1,000 mg of ceftolozane active present as ceftolozane sulfate, wherein the ceftolozane total purity is at least about 94% after storing the pharmaceutical composition for three days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.